http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Cara Therapeutics to Present at Upcoming Investor Conferences
-
Cara Therapeutics to Present at Upcoming Investor Conferences
-
Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
-
Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
-
Cara Therapeutics (CARA) Submits NDA for Difelikefalin in Japan
-
Cara Therapeutics (CARA) Announces Difelikefalin Injection New Drug Application Has Been Submitted in Japan
-
Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan
-
Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan
-
Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer
-
Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer
-
Cara Therapeutics (CARA) Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress
-
Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress
-
Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress
-
Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022
-
Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022
-
Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress
-
Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress
-
Cara Therapeutics (CARA) and Vifor Announces Kapruvia Approved in Switzerland
-
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
-
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
-
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
-
Cara Therapeutics Reports Second Quarter 2022 Financial Results
-
Cara Therapeutics Reports Second Quarter 2022 Financial Results
-
Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
-
Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
-
Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022
-
Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022
-
Cara Therapeutics (CARA) Reports Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin
-
Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica
-
Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica
-
Cara Therapeutics to Present at Upcoming Investor Conferences
-
Cara Therapeutics to Present at Upcoming Investor Conferences
-
Cara Therapeutics Reports First Quarter 2022 Financial Results
-
Cara Therapeutics Reports First Quarter 2022 Financial Results
-
Cara Therapeutics to Present at May Investor Conferences
-
Cara Therapeutics to Present at May Investor Conferences
-
Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
-
Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
-
Cara Therapeutics (CARA) and Vifor Announces Kapruvia Approved in EU for Treatment of Moderate-to-Sever Pruritus in Hemodialysis Patients
-
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
-
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
-
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
-
Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
-
Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
-
Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022
-
Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022
-
Cara Therapeutics (CARA) Announces Oral KORSUVA Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus
-
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus
